JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations
Conditions: Local Advanced or Metastatic NSCLC Interventions: Drug: JMT101 Injection; Drug: Osimertinib tablet; Drug: Cisplatin injection; Drug: Pemetrexed injection Sponsors: Shanghai JMT-Bio Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Research